HeartBeam (BEAT) said Monday its HeartBeam device has received 510(k) clearance from the US Food and Drug Administration for comprehensive arrhythmia assessment.
The device tracks heart signals from three directions to provide heart health information, the company said.
Shares of HeartBeam were up more than 11% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.